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Summary 
Tumor necrosis factor (TNF) is a potentially useful adjunct to anticancer therapies. However, 
the clinical utility of TNF has been limited by generalized toxicity and hypotension. Recently, 
studies have begun to dissect the individual proinflammatory and immunologic responses  that 
result from TNF binding to its two cellular receptors, p55 and p75, in an attempt to develop 
TNF receptor agonists  with reduced systemic toxicity. To evaluate a p75  receptor selective 
TNF mutant (p75TNF),  TNF  and p75TNF  were  administered to healthy anesthetized ba- 
boons. Intravenous infusion of the p75TNF produced none of the hemodynamic changes seen 
after the infusion of TNF. Infusion of p75TNF also failed to induce the plasma appearance of 
interleukins 6 and 8. However, p75TNF enhanced in vitro baboon thymocyte proliferation to 
concanavalin A, and infusion of p75TNF resulted in increased soluble p55  and p75  receptor 
plasma concentrations. Local skin necrosis and tissue neutrophil infiltration were seen after sub- 
cutaneous injections of TNF and p55TNF.  Subcutaneous injection of p75TNF did not result 
in skin necrosis but did result in a modest dermal infiltration oflymphocytes and macrophages. 
The findings suggest that p75TNF may stimulate T  cell proliferation without the systemic and 
local toxicity seen with TNF. 
T 
NF  was  first  identified  as  the  macrophage-derived 
product  responsible  for the  hemorrhagic  necrosis  of 
several murine solid tumors after endotoxin administration 
(1). More recently, TNF has been shown to mediate sev- 
eral diverse biologic effects including macrophage and PMN 
activation, chemoattraction, induction of endothelial adhe- 
sion molecules, apoptosis of certain tumor cells fines, lym- 
phocyte proliferation, and the release  of other proinflam- 
matory cytokines, most notably IL-113, IL-6, and IL-8 (1-4). 
TNF acts by binding to two cell surface receptors, iden- 
tified as p55  (type I) and p75  (type II).  The two receptors 
share similar cysteine-rich extracellular domains but dissim- 
ilar intracellular structures (5). TNF binding to the p55 re- 
ceptor induces apoptosis in some tumor cell lines,  the ex- 
pression of endothelial cell adhesion molecules, fibroblast 
proliferation, and neutrophil  activation  (4,  6-10).  Trans- 
genic mice with a nonfunctional gene coding for the p55 
receptor have been shown to be resistant to endotoxemic 
shock but are more susceptible  to Listeria infection (11, 12). 
TNF binding to the p75 receptor promotes in vitro thy- 
mocyte and circulating lymphocyte proliferation (13,  14). 
Binding to the p75 receptor mediates lysis of certain tumor 
cell lines in vitro alone and in conjunction with binding to 
the p55  receptor (2,  14,  15). However, knowledge of the 
in vivo function of the p75 TNF receptor is limited. Shee- 
han et al. (16) demonstrated that antibodies specific for the 
p75  TNF receptor protect mice from the development of 
skin necrosis after the subcutaneous administration of mu- 
fine TNF. Similar results have been obtained in transgenic 
mice with a nonfuctional p75 TNF receptor (17). 
Recently, human TNF mutants have been created that 
selectively bind only one of the two TNF receptors  (18). 
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subcutaneous administration  of a p75 TNF mutant (p75TNF) 
in healthy baboons, and its comparison to wild-type TNF. 
Materials  and Methods 
TNF, p55, and p 75 TNF Receptor  Agonists.  p55TNF,  p75TNF, 
and wild-type TNF were prepared as previously reported  (18). 
The p55TNF mutant was generated by site-specific mutagenesis 
of the human TNF cDNA with Arg  32 replaced by Trp, and Ser  86 
replaced by Thr (18). The p75TNF mutant was generated by re- 
placing Asp  143 with Asn, and Ala  14s with Arg. This p75TNF mu- 
tant has no affinity for the p55 TNF receptor while binding to 
the human p75 TNF receptor with about one tenth the affinity of 
wild-type TNF (18). 
Solid-phase Radioligand Binding Assay.  The specificity of p75- 
TNF for human and baboon p75  TNF receptors  was confirmed 
in competitive  radioligand binding assays as described (18). Briefly, 
TNF receptors  were extracted  with Triton X-100 from baboon 
buffy coats and HL60 cells, and immobilized to microtiter plates 
coated  with affinity-purified anti-human p55 and p75  TNF re- 
ceptor polyclonal antibodies. Binding of human lzSI-TNF (10 ng/ 
ml) to the receptors  was measured in the absence and presence of 
20 txg/ml recombinant human TNF and p75TNF. Bound radio- 
activity  was  quantitated in a Phosphorlmager  ~  (Molecular Dy- 
namics, Inc., Sunnyvale, CA). 
Thymocyte Proliferation Assay.  The thymocyte proliferation as- 
say was adapted  from Tartaglia  et al.  (14). Briefly, thymic tissue 
was obtained at necropsy from a young healthy Papio sp. baboon. 
Baboon thymocytes were isolated  by Dounce homogenization, 
and cells were plated in 96-well flat-bottomed plates at a density 
of 3  ￿  106 cells/ml to a final volume of 0.2 ml/well. The cells 
were cultured in RPMI 1640 supplemented with 10% heat-inac- 
tivated FCS,  1% glutamine, 100 U/ml penicillin, and 100 Ixg/ml 
streptomycin in the presence  of 2 t~g/ml purified Con A (Sigma 
Chemicals,  Co., St. Louis, MO). Serial dilutions of recombinant 
human TNF and p75TNF were added  in a concentration range 
of 1 to 10 -5, and 10 to 10 -4 I~g/ml, respectively.  The cells were 
incubated for  60  h  at  37~  and  pulsed  with  1  IxCi/well  of 
[3H]thyrnidine (Amersham Ltd. Norwalk, CT) for a further 18 h. 
The cells were then harvested from the 96-weU plate and precip- 
itated  with  10% TCA. Cell pellets  were washed,  solubilized  in 
normal NaOH, and counted in a liquid scintillation counter. 
Treatment Protocol of Baboons.  Juvenile (5-10-yr-old) Papio sp. 
animals were quarantined for at least 4--6 wk to confirm that they 
were healthy and free of pathogens.  The animals were housed at 
the  Research  Animal Resource  Center  of Cornell University 
Medical College  or the Health Science Center Animal Resource 
Department at the University of Florida.  The experimental pro- 
tocol was  approved by the  Institutional Animal Care  and Use 
Committees of Cornell University Medical College and the Uni- 
versity of Florida. 
In  the  studies  of  intravenous administration of  TNF  and 
p75TNF,  the  baboons were  anesthetized  and  instrumented as 
previously described (3). 
After  1 h  of equilibration, baseline  blood samples were  ob- 
tained,  l~ecombinant human TNF, p75TNF, or saline (control 
injection) was  administered intravenously in a blinded fashion. 
TNF was infused at a dose of 100 ~g/kg body weight, p75TNF 
was administered at a 10-fold-higher dose (1 mg/kg) to compen- 
sate for its ~10-fold-decreased binding affinity for the p75 recep- 
tor (18). Four baboons received TNF, three received p75TNF, 
and two baboons received placebo injections of saline. 
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Arterial  blood sampling was carried  out at the time of treat- 
ment and after 2 rain, 5 rain, 10 min, 30 rain, 1 h, 1.5 h, 2 hr, 2.5 h, 
3 h, 4 h, 5 h, 6 h, 7 h, and 8 h. Heparinized blood was centri- 
fuged at 2,500 rpm for 15 rain at 4~  and the plasma fraction all- 
quoted and stored at -70~  Plasma IL-6, IL-8, and IL-113 con- 
centrations were measured by ELISA as previously described (19). 
Plasma concentrations of the soluble p55 and p75 TNF receptors 
were also measured by ELISA using polyclonal rabbit antibodies 
(19). Endogenous TNF bioactivity was determined by incubating 
baboon plasma with the murine WEHI 164 clone 13 fibroblast 
cell line and determining cytotoxicity (3, 19), taking advantage of 
the  fact that neither p55TNF nor p75TNF is bioactive on the 
murine WEHI cell line (data not shown). Thus, WEHI cytotoxic 
activity in plasma samples from baboons treated  with p75TNF 
can be attributed to an endogenous Papio TNF response (3). This 
strategy cannot be used with plasma samples from baboons that 
have received recombinant human TNF, since both recombinant 
human TNF  and  endogenous baboon  TNF  are  cytotoxic  to 
WEHI 164 clone 13 cells. 
In two additional baboons, subcutaneous injections of recom- 
binant human TNF,  p55TNF,  p75TNF,  or  saline,  were  per- 
formed.  TNF, p55TNF, p75TNF, and a saline control in a vol- 
ume  of  200  ~1  were  injected  subcutaneously into  different 
regions on the medial aspect  of each  hind leg.  In one baboon, 
TNF  and  p55TNF  were  injected at  a  dose  of 0.1  p~g, and 
p75TNF was injected at 10-fold-higher doses (1.0 I-~g) in one leg. 
In the second baboon, TNF and p55TNF were given subcutane- 
ously at a dose of 10 p~g and the p75TNF was given at a dose of 
100 Ixg in one leg. Injection sites were identified with a perma- 
nent dye marker and were spaced at least 5 cm apart to avoid any 
diffusion of proteins between injection sites. Skin biopsies were 
taken 6 h after the injection. The tissue was fixed in buffered for- 
malin, embedded, sectioned,  and stained with hematoxylin and 
eosin.  On the contralateral  hind leg of each of the two animals, 
TNF, p55TNF, p75TNF, and saline were administered subcuta- 
neously at the high and low dose as before, but repeated  daily for 
4 d. Biopsy samples were obtained at the end of the fifth day and 
processed in an identical fashion as for the 6-h samples. Hematox- 
ylin and eosin stained sections were evaluated without knowledge 
of the treatment groups. 
Statistical Analysis.  Statistical analyses of the  values  obtained 
were carried out by one-way analysis of variance (ANOVA) 1 with 
posthoc  analysis by Dunnett's method,  and two-way ANOVA 
with posthoc  analysis by the  Student-Newman-Keuls method. 
Statistical significance was determined with a P value of <0.05. 
All values are expressed as mean +  standard error of the mean. 
Results 
Receptor-type Specificity  of p75TNF  in Papio.  p75TNF 
binds exclusively human p75 with an affinity of about one 
tenth of recombinant human TNF (18). To analyze whether 
the  receptor-type selectivity of p75TNF is  maintained in 
baboons, binding of p75TNF to human and baboon TNF 
receptors was compared in a solid-phase competitive bind- 
ing assay. As shown in Fig. 1, p75TNF inhibited binding of 
human 125I-TNF to p75 TNF receptor, but not to p55, re- 
gardless  of whether the  receptors  were  derived from hu- 
man HL60 cells or Papio leukocytes. Recombinant human 
TNF  competitively  blocked  binding  to  both  receptors 
1Abbreviations used in this  paper: ANOVA, analysis  of variance. 
Inflammation from both species. Because of the relatively low number of 
p75 present on the Papio leukocyte, the binding of~25I-TNF 
to these samples was low and,  as a consequence  the non- 
specifically bound radioactivity in these wells became more 
apparent (Fig. 1, bottom). Nevertheless, the competitive bind- 
ing assays clearly demonstrate a p75 selectivity of p75TNF 
in Papio, analogous to the earlier described p55TNF which 
also  maintained receptor-type selectivity in Papio (3).  lke- 
combinant human  TNF binds  to both Papio TNF recep- 
tors, p55 and p75. 
Thymocyte Proliferation.  Previous studies have suggested 
that TNF proliferative signals in lymphoid cells can be me- 
diated independently via the p75 (13,  14).  To determine if 
human p75TNF was active in Papio, thymocytes were iso- 
lated and proliferation was measured in vitro in response to 
p75TNF and TNF in the presence of suboptimal quantities 
of Con A.  It was found that both p75TNF  and TNF in- 
creased [3H]thymidine uptake by baboon thymocytes in a 
dose-dependent  manner  when  costimulated  with  Con  A 
(Fig.  2).  Peak incorporation  of [3H]thymidine with  TNF 
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Figure 1. 
humans. Solubilized HL60 and baboon leukocyte TNF receptors were 
captured on microtiter  plates coated  with affinity-purified  polyclonal  anti- 
bodies specific for human p55 and p75. Binding of human recombinant 
12SI-TNF (10 ng/ml) was determined in the presence or absence of excess 
unlabeled recombinant human TNF or p75TNF (2 I.tg/ml). The bound 
radioactivity in the absence of competitor  is taken as 100%; it was 1.35 X 
10  s and 1.05 ￿  106 Phosphorlmager  |  counts (p55TNF receptor; top), and 
14,850 and 121,380 counts (p75 TNF receptor; bottom) for baboon pe- 
ripheral blood mononuclear and HL60 cells, respectively. (Top) Binding 
competition to p55; (bottom)  binding competition to p75. 
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was seen with concentrations of 40 ng/ml. Further increas- 
ing the concentration of TNF led to decreased incorpora- 
tion of [3H]thymidine with a return to baseline stimulation 
by Con A alone at a dose of 10 I~g/ml. Similarly, p75TNF 
increased  [3H]thymidine  uptake,  but  as  expected,  higher 
concentrations  were  required.  [3H]Thymidine  incorpora- 
tion started to increase at 137 ng/ml, with maximal prolif- 
eration occurring at a concentration of 1,235 ng/ml. Stim- 
ulation  with higher  doses of the p75  agonist again led to 
decreased  [3H]thymidine uptake with a return  to baseline 
values of Con A alone at a concentration of 33 btg/ml. 
Hemodynamic Response.  Baboons treated with p75TNF 
developed only a mild tachycardia with a maximum peak 
increase in heart rate (22  +  7 beats/min)  1.5  and 2 h  after 
treatment (Fig. 3). The tachycardic response thus was much 
shorter  and  less  pronounced  than  in  the  animals  treated 
with TNF, but it was significantly different (P <0.05) from 
the  heart  rate  immediately before  the  p75TNF  infusion. 
The difference between the animals treated with p75TNF 
and TNF was statistically significant. 
Administration  of p75TNF  did  not  produce  hypoten- 
sion. The changes in mean arterial blood pressure were not 
significantly different from baseline or measurements from 
saline  control  animals.  The  maximal fall  in  mean  arterial 
blood pressure in the animals treated with p75TNF,  15  + 
5 tort, was significantly less (P <0.05)  in extent and dura- 
tion  than  what  had  been  seen  in  the  animals  receiving 
TNF. Animals receiving saline as a parallel placebo control 
developed  a  mild  tachycardia  and  a  fall  in  mean  arterial 
blood pressure that was not significantly different from val- 
ues  obtained  immediately  before  infusing  the  saline,  or 
from p75TNF-treated baboons, by one-way ANOVA. 
Core Body Temperature Response.  Administration  of TNF 
and p75TNF produced fever in the baboons (Table 1).  In 
contrast,  control  animals  administered  saline  had  only  a 
modest elevation. The fever curves of the animals treated 
with  TNF  and  p75TNF  were  not  significantly  different 
from each other by two-way ANOVA  (data not shown), 
but were different from the control animals. 
Proinflammatory CytokineResponse.  IL-I~  was  not  de- 
tected  in  any  of the  plasma  samples  after  either  TNF, 
p75TNF,  or saline infusions  (data not shown).  No signifi- 
cant release of circulating IL-6 and  IL-8 (Table  1)  or en- 
dogenous TNF response (i.e., WEHI cytotoxicity) was de- 
tected after infusion ofp75TNF or saline (data not shown). 
In contrast, ~ld-type TNF produced a significant appear- 
ance of IL-6 and IL-8 that peaked after 6 and 7 h, respec- 
tively. 
Administration  of TNF  and  p75TNF  both  resulted  in 
increased  plasma concentrations  of soluble  p55  and  p75, 
but  the  magnitude  of the  response was  much less  in  the 
p75TNF-treated animals  (Table  1).  The administration  of 
TNF caused a sustained increase of soluble p55 throughout 
the  8-h study period,  whereas administration  of p75TNF 
also resulted in the  transient increase in  soluble p55  con- 
centrations with the maximum being reached 1 h  after in- 
fusion (P <0.05  vs. baseline). Administration of TNF and 
p75TNF also resulted in increased plasma concentrations of --O--  TNFa 
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Figure  2.  Thymocyte  prolif- 
eration with recombinant human 
TNF and p75TNF  in the pres- 
ence of Con A. The thymus was 
removed from a healthy juvenile 
baboon after euthanasia and cells 
dispersed mechanically. 3 ￿  106 
cells/weU were incubated in 96- 
well microtiter plates with com- 
plete medium containing 1 p~g/ 
ml of Con A and increasing  con- 
centrations of recombinant  hu- 
man TNF or p75TNF for 60 h, 
pulsed  with  1 btCi of [3H]thy- 
midine for 18 h, and harvested as 
described in Materials and Meth- 
ods. Values are presented as mean 
cpm/well. 
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the soluble p75, but the response to p75TNF was dramati- 
cally lower than  that  of wild-type TNF  (Table  1).  There 
was  no  significant increase in the plasma concentration  of 
soluble p75 or p55 in the animals infused with saline alone. 
Subcutaneous Inflammatory Response.  The sequelae of sub- 
cutaneous injections ofTNF, p55TNF, and p75TNF at two 
doses were studied by histologic analysis. 6 h  after the sub- 
cutaneous injection of TNF  or p55TNF,  neutrophil infil- 
tration was noted (Fig. 4). At the low dose, p55TNF (0.1 p~g) 
led to margination of moderate numbers  of neutrophils in 
the  venules  with  perivenular  aggregation  and  edema.  In 
contrast, administration of the low doses of TNF  (0.1  ~zg) 
and p75TNF  (1  ~g), or saline, resulted in no significant le- 
sion after 6 h.  Injections of the high doses ofp55TNF  and 
TNF  (each 10 p~g) resulted in more pronounced histolog- 
ical  changes  6  h  after  treatment.  High  dose  TNF  led to 
margination of neutrophils with  perivenular aggregates of 
neutrophils,  similar to  the  low  dose  p55TNF  injections. 
p55TNF  at the high dose caused a similar but more severe 
lesion than  that  seen  after administration of the  low  dose 
p55TNF. The administration of high dose p75TNF (100 p,g) 
did not  result in  significant histological changes  6  h  after 
treatment (Fig. 4). 
The tissue reaction to repeated subcutaneous administra- 
tion  was  more  pronounced.  After daily injections  of the 
low  dose  of TNF  (0.1  p~g), no  histological changes  were 
Time In Hours 
Figure  3.  Hemodynamic changes in baboons treated with 100 v~g/kg 
BW recombinant human TNF, 1,000 p~g/kg  BW of p75TNF, or saline. 
(A) Changes in heart rate. (B) Changes in mean arterial pressure. Baboons 
treated  with  wild-type  TNF  (nv  =  4;  0-0);  animals treated  with 
p75TNF (n = 3; D-at), and baboons receiving only saline (n = 2; CYO). 
mean values •  SEM, except for the saline group (n =  2) which is stan- 
dard deviation. 
168  p75 Receptor Agonist and Inflammation Table 1.  Febrile  Response and Peak Plasma Cytokine Appearance 
in Baboons Treated with Wild-type TNF, p75TNF, or Saline 
Wild-type TNF  p75TNF  Saline 
(n =  4)  (n =  3)  (n =  2)* 
Change in body 
temperature (~  +2.7  +  0.1'  +2.0 +  0.2*  +1.2  +  0.4* 
IL-113, pg/ml  nd~  nd  nd 
IL-6, ng/ml  48.5  +  8.0*  0.3 +  0.03  0.2 +  0.07 
IL-8, ng/ml  14.3  +  2.0*  0.2 +  0.2  0 
Change in p55, 
pg/mlll  1,025  +  373*  553  +  57*  -8  -+ 74 
Change in p75, 
pg/rnlll  6,061  +  2,477*  537  •  132'  89 •  93 
*With an n =  2 in the sahne group, the variance reported is standard 
deviation. 
*Statistical difference from basehne measurements (i.e., time =  0 h) by 
one-way ANOVA and Student-Newman-Keuls  multiple range test. 
~Not detected with a sensitivity of 11 pg/ml. 
IIValues represent  a change  in baseline measurement  obtained  before 
protein administration. 
detected, but low dose (0.1  p,g) repeated administration of 
p55TNF  (0.1  p~g) caused multifocal, low density aggregates 
ofmononuclear cells and neutrophils. The repeated admin- 
istration of low dose p75TNF  (1  p~g) resulted in minimal 
multifocal low density aggregates oflymphocytes and mac- 
rophages in  the  superficial dermis.  There  were  no  signifi- 
cant  lesions  associated with  the  injection  of saline  alone. 
The  repeated  high  dose  administration  of p55TNF  and 
TNF  (each  10  p~g) resulted in clinically apparent, indistin- 
guishable macroscopic ulcerations of the overlying epider- 
mis and dermis with eschar formation. The ulcerations ap- 
peared  to  penetrate  partially  through  the  dermis  with 
extensive  fibrosis  of the  underlying  subcutaneous  tissue. 
Repeated  high  dose  administration of p75TNF  (100  p,g) 
and saline resulted in no macroscopic tissue changes. Histo- 
logically, repeated high  dose p55TNF  and  TNF  adminis- 
tration resulted in both superficial dermal coagulation and 
necrosis with  surrounding  areas of hemorrhage  and  dense 
surrounding  aggregates  of both  macrophages  and  neutro- 
phils (Fig. 4). The biopsy of skin treated after repeated high 
dose administration of p75TNF  (100  p,g)  revealed no  sig- 
nificant histological changes. 
Discussion 
The present studies dearly show that a p75  TNF  selec- 
tive agonist is not  nearly as toxic as wild-type TNF  with 
regard  to  its  capacity to  produce  hypotension  and  shock 
when administered systemically, and to produce inflamma- 
tion and tissue necrosis in the skin after subcutaneous injec- 
tion.  However,  the  p75  TNF  receptor  selective  agonist 
stimulates thymocyte proliferation in vitro, elicits a  febrile 
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Figure 4.  Histological changes after acute or chronic TNF or p75TNF 
administration. (A) Dermis from baboon having received 10 p,g p55TNF 
6 h before collection of the biopsy sample. A dermal venule is surrounded 
by and the wall infiltrated by dense aggregates of neutrophils. (*) Venule 
lumen; (1~) a lining endothelial cell. Hematoxyhn and eosin stained paraf- 
fin section. (B) Dermis from baboon having received 100 ~g p75TNF 6 h 
before collection of biopsy sample. A dermal venule has an open lumen 
(*) and easily identified endothelial lining (~) with no inflammatory cell 
infiltrate. (C) Dermis from baboon having received 10 p,g p55TNF daily 
for 5 d before collection of biopsy sample. The dermis contains dense ag- 
gregates ofmacrophages with scattered collections ofneutrophils. A focus 
of necrotic cells is presented in the lower left comer of the field. (A-C) 
￿ 
response in vivo,  and produces a  modest transient mono- 
nuclear cell infiltration when administered intradermally. 
Attempts to  use  TNF  as an  antitumor agent in humans 
have met with little success, due at least in part to dose-lim- 
iting toxicity (20-22). Recombinant human TNF adminis- tered systemically at doses >200  I~g/m  2 causes significant 
toxicity including  fever,  rigor,  nausea,  diarrhea,  and  hy- 
potension (20). However, regional administration of higher 
dose TNF in combination with chemotherapy and hyper- 
thermia more recently has shown high response rates in pa- 
tients with melanoma and sarcoma of the extremities (22). 
In  addition,  local  administration  of  TNF  has  recendy 
shown promising response rates in Kaposi's sarcoma, plas- 
macytomas,  ovarian  adenocarcinomas,  and  various  meta- 
static tumors in the liver (20,  21). Unfortunately, systemic 
leakage of regionally administered TNF has occasionally re- 
sulted in life-threatening complications including shock (20). 
Previous studies  have suggested that p55  plays the  pri- 
mary role in the proinflammatory properties of TNF (3, 4), 
and, conversely, the p75 TNF receptor promotes in vitro thy- 
mocyte proliferation as well as the proliferation of periph- 
era/T cell populations  (13,  14).  The results of the present 
study confirm that p75TNF, at doses equivalent to those of 
wild-type TNF or ofp55TNF mutants that produce signif- 
icant systemic toxicity (3), lacks systemic toxicity in the ba- 
boon. Because this study did not evaluate pharmacokinetic 
properties of p75TNF when compared with p55TNF and 
wild-type TNF,  and because a dose-response was not in- 
vestigated,  we  cannot  conclude  that  p75TNF  is  without 
any  systemic  toxicity.  However,  at  doses  of TNF  and 
p75TNF that are equivalent based upon their binding affin- 
ities (18),  only TNF produced significant systemic toxicity 
and skin inflammation. 
Previous  investigations  of the  local  inflammatory  re- 
sponse of skin to subcutaneous and intradermal injection of 
TNF had demonstrated that TNF leads to acute (within 8 h) 
neutrophil  margination  and  edema  formation  (23-25). 
More recent studies have demonstrated that when injected 
subcutaneously daily over 5-7 d, TNF causes skin necrosis 
and intense  neutrophil infiltration  (16,  17).  Two previous 
studies suggested that skin inflammation is partially depen- 
dent on TNF binding to the p75  TNF receptor, because 
mice  treated  with  antibodies  against  murine  p75  showed 
attenuated TNF-induced skin inflammation (16).  Similarly, 
transgenic  mice  lacking  a  functional  p75  had  attenuated 
skin  lesions  after  subcutaneous  TNF  administration  (17). 
Those  studies  clearly show  that  TNF  binding  to  a  func- 
tiona/p75 receptor promotes the complete manifestation of 
an inflammatory response elicited by p55 TNF receptor ac- 
tivation.  The  present  study  addresses  the  question  of 
whether  TNF binding  to  the  p75  TNF  receptor alone is 
sufficient to ehcit a skin inflammatory lesion. Clearly, sub- 
cutaneous  administration  of p55TNF  in  the  baboon  re- 
sulted  in  similar  histological  changes  as  seen  with  TNF, 
such as hemorrhage, necrosis, and dense aggregates of both 
macrophages  and  neutrophils.  In  contrast,  p75  activation 
merely produced a modest degree of mononuclear cell in- 
filtration.  Beyond  that  cellular recruitment  phenomenon, 
however, the manifestations of acute and chronic tissue re- 
action required p55 activation. 
This study cannot rigorously establish whether p55 TNF 
receptor activation alone is sufficient to  elicit a local skin 
inflammatory response, because it had been found in a pre- 
vious study (3) that systemic administration ofp55TNF elic- 
ited  an  endogenous  baboon  TNF  response  that  activated 
both baboon p55  and p75.  By analogy, subcutaneous  ad- 
ministration  of p55TNF  may  induce  local  baboon  TNF 
production  that  would  also  bind  to  p75.  Further  studies 
thus are required to establish whether manifestation of skin 
inflammatory responses is an exclusive p55-dependent func- 
tion or is dependent on TNF binding to both receptors. 
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